| Accession Number: | 0001209191-23-015873 |
| Date: | 2023-03-01 |
| Issuer: | KINNATE BIOPHARMA INC. (KNTE) |
| Original Submission Date: |
MELTZ MARK A
103 MONTGOMERY STREET, SUITE 150
THE PRESIDIO OF SAN FRANCISCO
SAN FRANCISCO, CA 94129
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2023-03-01 | F | 638 | d | $5.21 | 27,286 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|
| ID | footnote |
|---|---|
| f1 | the shares were forfeited to cover a tax obligation resulting form the quarterly vesting of rsu's granted to the reporting person by the issuer. |
| f2 | includes 21,875 shares represented by restricted stock units ("rsus"). each rsu represents the reporting person's right to receive one share of common stock of the issuer. a portion of the rsus vest each quarter, subject to the reporting person's continued service as of each vesting date. |
